Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma

University of Modena and Reggio Emilia12 enrolled

Overview

The purpose of this study is to assess the efficacy of two three-weekly 1.8 mg/kg Brentuximab vedotin administrations in untreated patients with Hodgkin Lymphoma (HL).

This is a multicenter pilot phase II trial assessing 2 administrations of Brentuximab vedotin followed by PET scan and subsequent standard treatment with ABVD ± Radiotherapy. 12 patients defined by inclusion and exclusion criteria will be enrolled in one year. All subjects will be followed for disease evaluation every 3 months for one year after end of therapy until disease progression, death, initiation of alternative therapy, withdrawal of consent, or end of study. For all study procedures patient will be assigned a Unique Subject Identifier (SID) number that will be used to identify the subject during the screening process and throughout study participation. A master log will be maintained of all consented subjects and will document all screening failures (i.e. subjects who are consented but do not meet study eligibility criteria). Study records such as case report forms (CRFs) may be maintained electronically and require the same security and confidentiality as paper. Clinical information will not be released without written permission of the subject/legal representative, except as specified in the informed consent form

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hodgkin Lymphoma

Interventions

Brentuximab vedotinDRUG

1.8 mg/kg, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: 2

ABVDDRUG

Doxorubicin 25 mg/m2 IV, Bleomycin 10,000 units/m2 IV, Vinblastine 6 mg/m2 IV, Dacarbazine 375 mg/m2 IV on days 1-15 of each 28 day cycle. Number of Cycles: 3 or 6 according to initial disease stage.

Eligibility

Sex: ALLMin age: 8 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Previously-untreated patients with classical Hodgkin Lymphoma according to the World Health Organisation (WHO) classification * Histologically confirmed CD30+ HL * Stage IA, IIA, IIIA * Absence of bulky disease * FDG-PET at baseline * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 * Life expectancy \> 6 months. * Age 18-70 years. * Patients must be available for periodic blood sampling, study-related assessments, and management of toxicity at the treating institution. * Females of childbearing potential must have a negative pregnancy test result within three days of enrollment. All patients must agree to use effective contraceptive methods (one for male and two for female) during the course of the study and for 6 months following the end of full treatment (Brentuximab vedotin + ABVD +/- Radiotherapy). * Written informed consent. * Required baseline laboratory data: Absolute neutrophil count ≥ 1000/μl Platelet count ≥ 50.000/ μl Serum bilirubin ≤ 1.5 times ULN Serum creatinine ≤ 1.5 times ULN Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN Exclusion Criteria: * Peripheral neuropathy \> Grade 1 * Histologic diagnosis different from Hodgkin Lymphoma * Compressive symptoms * Patients previously treated with any anti-CD30 antibody * Known human immunodeficiency virus (HIV) positive * Known hepatitis B surface antigen-positive, or known or suspected infection active hepatitis C * Patients with signs or symptoms of progressive multifocal leukoencephalopathy (PML) * Patients with known cerebral/meningeal disease.

Locations (3)

Institute of Hematology and Medical Oncology "L. e A. Seràgnoli" at the University of Bologna

Bologna, Italy

Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia

Modena, Italy

Hematology, Azienda Ospedaliera Arcispedale S.Maria Nuova IRCCS

Reggio Emilia, Italy

Outcomes

Primary Outcomes

Number of Participants with Complete Metabolic Response by FDG-PET

Complete Metabolic Response will be defined by Deauville score 1, 2, 3.

Time frame: between day +8 and day +15 from second administration of Brentuximab

Secondary Outcomes

Overall Response Rate (ORR)

Time frame: Up to 4 weeks from the end of full treatment program.

Progression Free Survival (PFS)

Time frame: at 1 year from the end of full treatment program.

Number of Participants with Adverse Events

All serious and on-serious adverse events will be assessed

Time frame: from C1D1 of Brentuximab vedotin up to 1 year from the end of full treatment program.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.